These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22096965)

  • 1. [Interferon therapy for chronic hepatitis B].
    Hige S; Sho T; Nakanishi M; Chuma M
    Nihon Rinsho; 2011 May; 69 Suppl 4():481-5. PubMed ID: 22096965
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacological agents for the treatment of chronic hepatitis B].
    Sánchez-Tapias JM
    Gastroenterol Hepatol; 2008 Mar; 31(3):120-8. PubMed ID: 18341843
    [No Abstract]   [Full Text] [Related]  

  • 4. [Interferon therapy for chronic hepatitis B].
    Tang WL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Orlent H
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16224825
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antiviral therapy in children with chronic hepatitis B and children with chronic hepatitis C].
    Zhang H; Zhu S
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):563-6. PubMed ID: 25224229
    [No Abstract]   [Full Text] [Related]  

  • 7. [Protocol for the antiviral therapy of chronic hepatitis B].
    ;
    Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
    [No Abstract]   [Full Text] [Related]  

  • 8. Sequential Therapy with PEG-IFN alpha-2a and Tenofovir in a Hepatitis B Virus-Infected African Man.
    Cainelli F; Vento S
    Isr Med Assoc J; 2015 Dec; 17(12):790. PubMed ID: 26897988
    [No Abstract]   [Full Text] [Related]  

  • 9. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Cooksley G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleus(t)ide analogues in HBeAg positive chronic hepatitis B patients].
    Wang SQ; Xu KJ; Wu JZ; Liu XS; Luo TT; Yang RG; Geng XX; Huang RG; Lin JM; Jiang N
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):785-6. PubMed ID: 22423366
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.
    Emara MH; Radwan MI
    Virol J; 2011 Nov; 8():518. PubMed ID: 22078891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir.
    Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL
    Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of hepatitis B virus infection].
    Trautwein C
    Praxis (Bern 1994); 2006 Sep; 95(36):1389-97. PubMed ID: 16989182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.
    Brunetto MR; Oliveri F; Colombatto P; Coco B; Ciccorossi P; Bonino F
    J Hepatol; 2003; 39 Suppl 1():S164-7. PubMed ID: 14708697
    [No Abstract]   [Full Text] [Related]  

  • 17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B.
    Papadopoulos V; Protopapas A; Tsianos E; Mimidis K
    Scand J Gastroenterol; 2009; 44(8):1021-2. PubMed ID: 19424932
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Song K; Rajvanshi P
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16221792
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
    Tornai I
    Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.